Loading…

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery

Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2019-05, Vol.9 (3), p.16967-16976
Main Authors: Pei, Haixiang, Peng, Yangrui, Zhao, Qiuhua, Chen, Yihua
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93
cites cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93
container_end_page 16976
container_issue 3
container_start_page 16967
container_title RSC advances
container_volume 9
creator Pei, Haixiang
Peng, Yangrui
Zhao, Qiuhua
Chen, Yihua
description Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach. An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.
doi_str_mv 10.1039/c9ra03423d
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1039_C9RA03423D</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2241344122</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</originalsourceid><addsrcrecordid>eNp9kd1LHDEUxUNpqaK-9L2S0pcirOZjkp34UFhWbQVB8eM5ZJI7syOZyZrMCPvfN7p2a33wvtwL58fhHg5CXyg5pISrI6uiIbxg3H1A24wUcsKIVB9f3VtoL6V7kkcKyiT9jLa4EFSVU7GN7m464z3uggc7esBX15e3s3k6xqbH0EFs2r7BA9hFH3xoVrgOEQ8mNjCAw8MColmucNtjF8cGuzbZ8AhxtYs-1cYn2HvZO-ju7PR2_ntycfnrfD67mFjByDBhllDnJKkLmS9VWeWYEhVzFZSydKYSAqggoqTSOZBTI6BgMDU1KcGwWvEd9HPtuxyrDpyFfojG62VsOxNXOphW_6_07UI34VErIgupeDb48WIQw8MIadBdzgDemx7CmDSTkpKSKc4y-v0Neh_G2Od4mrGC8qKg7Ik6WFM2hpQi1JtnKNFPhem5up49F3aS4f3X72_Qv_Vk4OsaiMlu1H-NZ_3be7peupr_AfSZpls</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241344122</pqid></control><display><type>article</type><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><source>PubMed Central</source><creator>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</creator><creatorcontrib>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</creatorcontrib><description>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach. An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</description><identifier>ISSN: 2046-2069</identifier><identifier>EISSN: 2046-2069</identifier><identifier>DOI: 10.1039/c9ra03423d</identifier><identifier>PMID: 35519875</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Bioavailability ; Chemistry ; Monoclonal antibodies ; New technology ; Proteins</subject><ispartof>RSC advances, 2019-05, Vol.9 (3), p.16967-16976</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2019</rights><rights>This journal is © The Royal Society of Chemistry 2019 The Royal Society of Chemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</citedby><cites>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</cites><orcidid>0000-0003-4031-447X ; 0000-0003-1733-7980</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064693/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064693/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35519875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pei, Haixiang</creatorcontrib><creatorcontrib>Peng, Yangrui</creatorcontrib><creatorcontrib>Zhao, Qiuhua</creatorcontrib><creatorcontrib>Chen, Yihua</creatorcontrib><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><title>RSC advances</title><addtitle>RSC Adv</addtitle><description>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach. An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</description><subject>Bioavailability</subject><subject>Chemistry</subject><subject>Monoclonal antibodies</subject><subject>New technology</subject><subject>Proteins</subject><issn>2046-2069</issn><issn>2046-2069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kd1LHDEUxUNpqaK-9L2S0pcirOZjkp34UFhWbQVB8eM5ZJI7syOZyZrMCPvfN7p2a33wvtwL58fhHg5CXyg5pISrI6uiIbxg3H1A24wUcsKIVB9f3VtoL6V7kkcKyiT9jLa4EFSVU7GN7m464z3uggc7esBX15e3s3k6xqbH0EFs2r7BA9hFH3xoVrgOEQ8mNjCAw8MColmucNtjF8cGuzbZ8AhxtYs-1cYn2HvZO-ju7PR2_ntycfnrfD67mFjByDBhllDnJKkLmS9VWeWYEhVzFZSydKYSAqggoqTSOZBTI6BgMDU1KcGwWvEd9HPtuxyrDpyFfojG62VsOxNXOphW_6_07UI34VErIgupeDb48WIQw8MIadBdzgDemx7CmDSTkpKSKc4y-v0Neh_G2Od4mrGC8qKg7Ik6WFM2hpQi1JtnKNFPhem5up49F3aS4f3X72_Qv_Vk4OsaiMlu1H-NZ_3be7peupr_AfSZpls</recordid><startdate>20190530</startdate><enddate>20190530</enddate><creator>Pei, Haixiang</creator><creator>Peng, Yangrui</creator><creator>Zhao, Qiuhua</creator><creator>Chen, Yihua</creator><general>Royal Society of Chemistry</general><general>The Royal Society of Chemistry</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4031-447X</orcidid><orcidid>https://orcid.org/0000-0003-1733-7980</orcidid></search><sort><creationdate>20190530</creationdate><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><author>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bioavailability</topic><topic>Chemistry</topic><topic>Monoclonal antibodies</topic><topic>New technology</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pei, Haixiang</creatorcontrib><creatorcontrib>Peng, Yangrui</creatorcontrib><creatorcontrib>Zhao, Qiuhua</creatorcontrib><creatorcontrib>Chen, Yihua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>RSC advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pei, Haixiang</au><au>Peng, Yangrui</au><au>Zhao, Qiuhua</au><au>Chen, Yihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</atitle><jtitle>RSC advances</jtitle><addtitle>RSC Adv</addtitle><date>2019-05-30</date><risdate>2019</risdate><volume>9</volume><issue>3</issue><spage>16967</spage><epage>16976</epage><pages>16967-16976</pages><issn>2046-2069</issn><eissn>2046-2069</eissn><abstract>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach. An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>35519875</pmid><doi>10.1039/c9ra03423d</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4031-447X</orcidid><orcidid>https://orcid.org/0000-0003-1733-7980</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2046-2069
ispartof RSC advances, 2019-05, Vol.9 (3), p.16967-16976
issn 2046-2069
2046-2069
language eng
recordid cdi_crossref_primary_10_1039_C9RA03423D
source PubMed Central
subjects Bioavailability
Chemistry
Monoclonal antibodies
New technology
Proteins
title Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20molecule%20PROTACs:%20an%20emerging%20technology%20for%20targeted%20therapy%20in%20drug%20discovery&rft.jtitle=RSC%20advances&rft.au=Pei,%20Haixiang&rft.date=2019-05-30&rft.volume=9&rft.issue=3&rft.spage=16967&rft.epage=16976&rft.pages=16967-16976&rft.issn=2046-2069&rft.eissn=2046-2069&rft_id=info:doi/10.1039/c9ra03423d&rft_dat=%3Cproquest_cross%3E2241344122%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2241344122&rft_id=info:pmid/35519875&rfr_iscdi=true